Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Zhao, Shengqiang ^a   Wang, Jing ^a   Qin, Chengyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

CXC chemokine ligand 12 (CXCL12) chemokine receptor type 4 (CXCR4); Intrahepatic cholangiocarcinoma (IHCC); Metastasis; Prognosis; Wnt pathway

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR SLUG; VIMENTIN; WNT PROTEIN; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1; TUMOR MARKER;

ADULT; AGE; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENDER; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING; WOUND HEALING; ANIMAL; BILE DUCT NEOPLASMS; CELL MOTION; CHOLANGIOCARCINOMA; DISEASE COURSE; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; RNAI THERAPEUTICS; SECONDARY; TIME; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANIMALS; BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL12; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTORS, CXCR4; RNA INTERFERENCE; RNAI THERAPEUTICS; TIME FACTORS; TRANSFECTION; WNT SIGNALING PATHWAY;

EID: 84965183666     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0103-8     Document Type: Article

References (62)

1. Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, Batra SK, Yonezawa S: Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology 2012, 79:101-106.
2. Okuda K, Nakanuma Y, Miyazaki M: Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 2002, 17:1056-1063.
3. Okuda K, Nakanuma Y, Miyazaki M: Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002, 17:1049-1055.
4. Leelawat K, Keeratichamroen S, Leelawat S, Tohtong R: CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncol Lett 2013, 6:1439-1446.
5. Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, Bhat K, Wang F, Wu E, Wang Z: SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 2012, 322:169-176.
6. Holland JD, Gyorffy B, Vogel R, Eckert K, Valenti G, Fang L, Lohneis P, Elezkurtaj S, Ziebold U, Birchmeier W: Combined Wnt/beta-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep 2013, 5:1214-1227.
7. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, Parmentier M, Arenzana-Seisdedos F: Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 1998, 426:271-278.
8. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
9. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M: Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007, 109:2392-2404.
10. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
11. Burger JA, Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
12. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM: A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013, 49:219-230.
13. Hall JM, Korach KS: Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003, 17:792-803.
14. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62:1832-1837.
15. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005, 97:1840-1847.
16. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008, 25:201-211.
17. Sun J, Feng C, Liao W, Zhang H, Tang S: Expression of CXC chemokine receptor-4 and forkhead box 3 in neuroblastoma cells and response to chemotherapy. Oncol Lett 2014, 7:2083-2088.
18. Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV: CXCR4 receptor expression on human retinal pigment epithelial cells from the blood-retina barrier leads to chemokine secretion and migration in response to stromal cell-derived factor 1 alpha. J Immunol 2000, 165:4372-4378.
19. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
20. Burger JA, Peled A: CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
21. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
22. Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, Yang Q, Wang Z: MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway. Oncogene 2014, 33:5017-5027.
23. Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S, Yao J: Blockade of SDF-1/ CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer 2008, 99(10):1695-1703.
24. Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, Yang Q, Wang Z: MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway. Oncogene 2014, 33:5017-5027.
25. Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H, Tian T, Ruan ZP, Kang XM, Wang J, Wang SH, Nan KJ: SDF-1/CXCR4 promotes epithelialmesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett 2014, 354:417-426.
26. Wang J, Cai J, Han F, Yang C, Tong Q, Cao T, Wu L, Wang Z: Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int J Gynecol Cancer 2011, 21:981-987.
27. Tamura M, Sato MM, Nashimoto M: Regulation of CXCL12 expression by canonical Wnt signaling in bone marrow stromal cells. Int J Biochem Cell Biol 2011, 43:760-767.
28. Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K, Kozaka K, Ishikawa A, Oda K, Nimura Y, Nakanuma Y: Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol 2006, 168:1155-1168.
29. Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, Marra F, Mantero S, Roncalli M, Invernizzi P, Pinzani M: Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol 2012, 57:813-820.
30. Tan XY, Chang S, Liu W, Tang HH: Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma. Gut Liver 2014, 8:196-204.
31. Okamoto K, Tajima H, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Nakamura K, Oyama K, Nakagawara H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Harada S, Wakayama T, Iseki S, Ohta T: Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol 2012, 41:573-582.
32. Zhao S, Zhou L, Niu G, Li Y, Zhao D, Zeng H: Differential regulation of orphan nuclear receptor TR3 transcript variants by novel vascular growth factor signaling pathways. FASEB J 2014, 28:4524-4533.
33. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513-13518.
34. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612.
35. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M, Melillo RM: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 2007, 67:11821-11829.
36. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ: Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009, 69:1460-1469.
37. Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, Basik M: CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011, 129:225-232.
38. Zeelenberg IS, Ruuls-Van Stalle L, Roos E: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003, 63:3833-3839.
39. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
40. Konopleva MY, Jordan CT: Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011, 29:591-599.
41. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF: Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
42. Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J, Qiu F: Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer 2014, 14:49.
43. Liu CF, Liu SY, Min XY, Ji YY, Wang N, Liu D, Ma N, Li ZF, Li K: The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PLoS One 2014, 9:e92629.
44. Woerner BM, Warrington NM, Kung AL, Perry A, Rubin JB: Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 2005, 65:11392-11399.
45. Chang B, Kim J, Jeong D, Jeong Y, Jeon S, Jung SI, Yang Y, Kim KI, Lim JS, Kim C, Lee MS: Klotho inhibits the capacity of cell migration and invasion in cervical cancer. Oncol Rep 2012, 28:1022-1028.
46. Huang CL, Liu D, Ishikawa S, Nakashima T, Nakashima N, Yokomise H, Kadota K, Ueno M: Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 2008, 44:2680-2688.
47. Doucas H, Garcea G, Neal CP, Manson MM, Berry DP: Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 2005, 41:365-379.
48. Kolligs FT, Bommer G, Goke B: Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 2002, 66:131-144.
49. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
50. Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M: Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006, 94:1816-1822.
51. Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S: Activation of NF-kappaB by the RANKL/RANK system upregulates snail and twist expressions and induces epithelial-tomesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res 2013, 32:62.
52. Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao HZ, Li DM, Zhao Q: Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res 2012, 31:29.
53. Kaufhold S, Bonavida B: Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res 2014, 33:62.
54. Li M, Zhang B, Sun B, Wang X, Ban X, Sun T, Liu Z, Zhao X: A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J Exp Clin Cancer Res 2010, 29:109.
55. Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A: CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell 2014, 25:566-582.
56. Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, Xu XD, Yu ED, Rui YC, Liu HJ, Zhang L, Wei LX: CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012, 10:85.
57. Fanelli MF, Chinen LT, Begnami MD, Costa WL Jr, Fregnami JH, Soares FA, Montagnini AL: The influence of transforming growth factor-alpha, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology 2012, 61:153-161.
58. Bertran E, Caja L, Navarro E, Sancho P, Mainez J, Murillo MM, Vinyals A, Fabra A, Fabregat I: Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 2009, 21:1595-1606.
59. Taki M, Higashikawa K, Yoneda S, Ono S, Shigeishi H, Nagayama M, Kamata N: Up-regulation of stromal cell-derived factor-1alpha and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep 2008, 19:993-998.
60. Onoue T, Uchida D, Begum NM, Tomizuka Y, Yoshida H, Sato M: Epithelialmesenchymal transition induced by the stromal cell-derived factor-1/ CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol 2006, 29:1133-1138.
61. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012, 119:3917-3924.
62. Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, Stille JR, Saleh M, Thornton D: A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer. Clin Cancer Res 2014, 20(13):3581-3588.